Susquehanna International Group
TAK icon

Susquehanna International Group’s Takeda Pharmaceutical TAK Stock Holding History

Susquehanna International Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$411K Buy
+22,200
New +$390K ﹤0.01% 10142
2025
Q4 		– Sell
-43,800
Closed -$641K – 13596
2025
Q3 		$641K Sell
43,800
-788,500
-95% -$11.7M ﹤0.01% 8404
2025
Q2 		$12.9M Buy
832,300
+810,100
+3,649% +$12M ﹤0.01% 2522
2025
Q1 		$330K Buy
+22,200
New +$311K ﹤0.01% 9861
2024
Q2 		– Sell
-31,100
Closed -$432K – 13212
2024
Q1 		$432K Sell
31,100
-62,400
-67% -$907K ﹤0.01% 8867
2023
Q4 		$1.33M Sell
93,500
-900
-1% -$12.8K ﹤0.01% 6272
2023
Q3 		$1.46M Sell
94,400
-146,700
-61% -$2.27M ﹤0.01% 5791
2023
Q2 		$3.79M Buy
241,100
+197,300
+450% +$3.23M ﹤0.01% 3981
2023
Q1 		$722K Sell
43,800
-1,019,100
-96% -$16.2M ﹤0.01% 7646
2022
Q4 		$16.6M Buy
1,062,900
+927,200
+683% +$13M ﹤0.01% 1701
2022
Q3 		$1.76M Sell
135,700
-1,252,100
-90% -$17.4M ﹤0.01% 5194
2022
Q2 		$19.5M Buy
1,387,800
+61,400
+5% +$876K ﹤0.01% 1474
2022
Q1 		$19M Buy
1,326,400
+676,000
+104% +$9.93M ﹤0.01% 1785
2021
Q4 		$8.87M Buy
650,400
+75,500
+13% +$1.06M ﹤0.01% 2895
2021
Q3 		$9.42M Sell
574,900
-21,600
-4% -$363K ﹤0.01% 2956
2021
Q2 		$10M Sell
596,500
-144,400
-19% -$2.46M ﹤0.01% 2909
2021
Q1 		$13.5M Sell
740,900
-142,500
-16% -$2.56M ﹤0.01% 2355
2020
Q4 		$16.1M Buy
883,400
+488,200
+124% +$8.57M ﹤0.01% 1976
2020
Q3 		$7.05M Buy
395,200
+22,900
+6% +$417K ﹤0.01% 2637
2020
Q2 		$6.68M Sell
372,300
-35,000
-9% -$628K ﹤0.01% 2627
2020
Q1 		$6.18M Sell
407,300
-350,900
-46% -$6.36M ﹤0.01% 2308
2019
Q4 		$15M Buy
758,200
+14,000
+2% +$268K ﹤0.01% 1686
2019
Q3 		$12.8M Sell
744,200
-72,100
-9% -$1.25M ﹤0.01% 1725
2019
Q2 		$14.4M Buy
816,300
+102,500
+14% +$1.87M 0.01% 1547
2019
Q1 		$14.5M Buy
713,800
+565,200
+380% +$11.4M 0.01% 1424
2018
Q4 		$2.5M Buy
+148,600
New +$2.51M ﹤0.01% 3194

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's TAK Position: Q1 2026 in Review

Susquehanna International Group increased its Takeda Pharmaceutical (TAK) stake by 44% in Q1 2026, buying an estimated $224K and bringing the position to 41,424 shares worth $767K. The position accounts for ﹤0.01% of the portfolio, ranked #8581.

Susquehanna International Group first reported a position in TAK in Q2 2019 and has held it in 25 quarters since. The position peaked at $28.1M in Q1 2021. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Susquehanna International Group held 41,424 shares of Takeda Pharmaceutical worth $767K as of Q1 2026.
  • Susquehanna International Group bought 12,749 Takeda Pharmaceutical shares in Q1 2026, an estimated $224K.
  • Takeda Pharmaceutical made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8581 holding.
  • Susquehanna International Group first reported a position in Takeda Pharmaceutical in Q2 2019 and has held it in 25 quarters since.
  • Susquehanna International Group's Takeda Pharmaceutical position peaked at $28.1M in Q1 2021.
  • 359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.